Answers are grounded in this paper and cite their sources.
Whole-plant extracts are often treated as phytochemical ensembles whose effects may exceed those of single constituents, yet the field lacks a framework specifying what evidence would confirm or refute ensemble action. Portulaca oleracea L. illustrates this gap: its chemistry is well cataloged, but no study has compared whole extract with purified constituents at matched target-tissue exposure, so whether the whole outperforms its parts remains untested. We define the phytochemical ensemble by three criteria that distinguish it from additive, pairwise-synergistic, trace-compound, and batch-variation explanations, and we propose convergence, pharmacokinetic complementarity, and emergence as its three pillars. Three propositions follow, each with explicit falsification criteria and a critical experiment. Proposition 1 (stoichiometric balance and multi-node convergence) is foundational and is the only framework-refuting proposition: the framework is falsified if a perturbed ratio nonetheless matches the native activity profile, if single-node ablation abolishes efficacy, or if a single constituent reproduces the extract’s effect at matched exposure. Proposition 2 is mechanistic and is subdivided into Proposition 2a (pharmacokinetic complementarity) and Proposition 2b (microbiome mediation); failure of either weakens, but does not falsify, the framework. Proposition 3 (whole-extract superiority via physiological integration) is indication-specific. We propose an Ensemble Fidelity Score (EFS), a prototype metric that jointly requires chemical and functional fidelity, together with a clinical design comparing whole extract with a purified constituent at matched exposure. The framework is designed to be falsifiable; either outcome advances the field.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: